Related Experiment Video

Updated: Jul 12, 2026

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
09:16

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells

Published on: September 1, 2019

Down-regulation of WT1/+17AA gene expression using RNAi and modulating leukemia cell chemotherapy resistance

Huiling Shen, Wenlin Xu, Zhaoyang Wu

    Haematologica
    |September 5, 2007
    PubMed

    Insights

    Inhibition of WT1/+17AA protein reduces multidrug resistance markers and enhances chemotherapy effectiveness in leukemia cells. This suggests WT1/+17AA drives cancer growth by affecting drug resistance.

    Area of Science:

    • Molecular Biology
    • Oncology
    • Cell Biology

    Background:

    • The Wilms tumor 1 (WT1) gene and its splice variants, such as WT1/+17AA, are implicated in various cancers, including leukemia.
    • Multidrug resistance (MDR) is a significant challenge in cancer chemotherapy, limiting the efficacy of treatments like doxorubicin.

    Discussion:

    • This study investigates the role of WT1/+17AA protein in modulating MDR in K562 leukemia cells.
    • Small interfering RNA (siRNA) technology was employed to inhibit WT1/+17AA expression, allowing for the assessment of its downstream effects.

    Key Insights:

    • Inhibiting WT1/+17AA expression led to decreased levels of MDR1 and P-glycoprotein, key mediators of drug efflux.
    • Concurrently, inhibition resulted in increased intracellular accumulation of Rhodamine 123 (Rh123), a substrate for P-glycoprotein.
    • This modulation of MDR markers significantly enhanced the cytotoxicity of doxorubicin, a common chemotherapeutic agent.

    Outlook:

    • These findings highlight WT1/+17AA as a potential therapeutic target for overcoming multidrug resistance in leukemia.
    • Further research could explore strategies to specifically target WT1/+17AA in combination therapies to improve patient outcomes.

    More Related Videos

    Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

    Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

    Published on: June 17, 2022

    Related Concept Videos

    Canonical Wnt Signaling Pathway02:54

    Canonical Wnt Signaling Pathway

    The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which results in tumor...
    Experimental RNAi02:15

    Experimental RNAi

    RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
    MicroRNAs01:22

    MicroRNAs

    MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
    MicroRNAs01:22

    MicroRNAs

    MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
    Regulation of Expression at Multiple Steps01:23

    Regulation of Expression at Multiple Steps

    The gene expression in cells is regulated at different stages: (i) transcription, (ii) RNA processing, (iii) RNA localization, and (iv) translation. Transcriptional regulation is mediated by regulatory proteins such as transcription factors, activators, or repressors—these control gene expression by initiating or inhibiting the transcription of genes. Once a precursor or pre-mRNA is produced, it undergoes post-transcriptional modification, including 5' capping, splicing, and the addition of a...